FOLLICULAR LYMPHOMA

This study tests a combination of two drugs, ixazomib and rituximab, in people with slow-growing B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with different types of this lymphoma are taking part.

This study is for people with follicular lymphoma, a type of blood cancer, that has come back or no longer responds to treatment. It tests whether adding the drug tazemetostat to standard therapy (lenalidomide plus rituximab) helps keep the cancer from growing longer than the sta…

This early-phase trial is testing whether combining three drugs—tazemetostat, zanubrutinib, and an anti-CD20 antibody (rituximab or obinutuzumab)—is safe and effective for people with certain types of lymphoma that have come back or not responded to treatment. The study involves …

This early-stage trial is testing a new drug called valemetostat together with two standard drugs (rituximab and lenalidomide) in 60 adults with follicular lymphoma that has come back or not responded to prior treatment. The main goal is to find a safe dose and check for side eff…

This phase 2 trial is testing a new drug called zilovertamab vedotin (MK-2140), alone or with another drug nemtabrutinib, in about 189 people with several types of B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to see if the trea…

This phase 3 trial compares a shorter chemotherapy regimen (4 cycles) against the standard 6 cycles, both combined with immunotherapy, for people with newly diagnosed, high-tumor-burden follicular lymphoma. The goal is to see if the shorter treatment is just as effective at keepi…

This early-phase study tests a new drug called BGB-11417 (sonrotoclax) in people with B-cell blood cancers that have come back or not responded to treatment. The goal is to find the safest dose and see how well it works alone or combined with other drugs. About 437 adults will ta…

This early-stage trial is testing a new drug called AZD0486 in about 226 people with B-cell non-Hodgkin lymphoma, including types like diffuse large B-cell lymphoma and follicular lymphoma. The drug is a bispecific antibody designed to help the body's immune T-cells recognize and…

This trial explores whether adding the drug tazemetostat (Tazverik) to standard CAR T cell therapy can help the immune cells better recognize and destroy lymphoma cells. It enrolls people with diffuse large B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma who have al…

This study tests two drugs, mosunetuzumab and lenalidomide, together in people with follicular lymphoma, a type of blood cancer. It includes 237 participants and compares giving one drug as a shot under the skin versus through an IV. The goal is to see if the combination is safe …

This early-phase trial tests whether adding special immune cells called veto cells to a stem cell transplant can help donor cells grow in the patient without causing severe graft-versus-host disease (GVHD). The study includes 16 people with various blood cancers or bone marrow fa…

This study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial,…

This study tests a new drug called orelabrutinib in people with B-cell malignancies, such as certain lymphomas and leukemias. The drug works by blocking a protein that helps cancer cells grow. The trial has two parts: first finding the safest dose, then seeing how well it shrinks…

This study tests a drug called epcoritamab, alone or with other treatments, in people with B-cell non-Hodgkin lymphoma, a type of blood cancer. The goal is to find the best dose and see how well it works. About 543 participants will receive the drug under the skin or through an I…

This trial tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has returned or not improved after standard treatment. The study has two parts: first, finding a safe dose, and then checking how well the drug works alone or with other chemotherapy.…

This phase 2 trial tests a drug called mosunetuzumab, given as a shot under the skin, for people with certain types of non-Hodgkin lymphoma. The study includes 320 participants and aims to see if the drug can shrink tumors or delay cancer growth. Researchers are also checking for…

This study tests the safety and effectiveness of tafasitamab, given alone or with other drugs (lenalidomide, parsaclisib, or R-CHOP), in about 72 Japanese adults with Non-Hodgkin lymphoma. The goal is to find the best doses and see if the treatment shrinks tumors. Participants ha…

This study tests whether combining two drugs, epcoritamab and lenalidomide, can shrink or eliminate tumors in people with untreated follicular lymphoma, a slow-growing blood cancer that is not currently curable. About 29 adults with stage 1-3a disease who need treatment will rece…

This study looks at how well the drug tazemetostat works in adults with a slow-growing blood cancer called follicular lymphoma that has returned or not responded after at least two prior treatments. Participants take tazemetostat as prescribed by their doctor in normal medical pr…

This early-stage study tests a new drug, BGB-11417, in 64 adults with B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to find the safest dose and understand side effects. Researchers will also look for signs that the drug shrinks …

This early-phase trial tests a two-part treatment for people with relapsed or chemotherapy-resistant B-cell leukemia or lymphoma. First, patients receive a chemotherapy drug (cyclophosphamide) to help prepare the body. Then, they get an infusion of their own T cells that have bee…

This study tests whether combining two drugs, obinutuzumab and CC-99282, can control follicular lymphoma in people with a high tumor burden who have not had prior treatment. About 33 adults with stage II–IV disease will receive the combination and be monitored for side effects an…

This phase II trial is testing a combination of two drugs—tazemetostat pills and mosunetuzumab injections—in 23 people with follicular lymphoma who have not yet received treatment. The goal is to see if the combination is safe and leads to a complete response (disappearance of ca…

This early-phase study tests a personalized cancer vaccine designed to target each patient's unique tumor mutations. It is given along with pembrolizumab after standard rituximab treatment for follicular lymphoma. The goal is to see if this approach is feasible and can boost the …

This phase 2 trial is testing a combination of two immunotherapy drugs, glofitamab and obinutuzumab, as the first treatment for people with follicular lymphoma or marginal zone lymphoma. The study includes 47 participants who have not had prior therapy for their lymphoma. The goa…

This phase 2 trial tests whether combining copanlisib and rituximab can slow or stop follicular lymphoma in people who haven't had treatment yet. About 33 participants will receive the drugs through an IV over several cycles. The main goal is to see how many achieve a complete re…

This study tests an experimental drug called valemetostat tosylate in people with B-cell lymphoma whose cancer has returned or not responded to prior treatments. About 141 participants will receive the drug to see if it can shrink tumors. The goal is to find a new option for hard…

This study tests a new drug combination for people with a type of slow-growing blood cancer called follicular lymphoma that has a high tumor burden. The treatment adds tazemetostat (a targeted pill) to a standard chemo-immunotherapy regimen, but uses a shorter course of chemother…

This study tests an experimental drug called WTX-330 in 100 adults with advanced solid tumors or non-Hodgkin lymphoma that have not responded to standard treatments. The trial has two parts: first, finding the safest dose and schedule, then expanding to see how well the drug work…

This was a phase 2 study testing the oral drug tazemetostat in adults with relapsed or refractory follicular lymphoma whose tumors lack an EZH2 gain-of-function mutation. The drug is already approved for this cancer, but researchers wanted to see how well it works in this specifi…

This study looks at whether giving a pneumonia vaccine (PCV13) before and after CAR T-cell therapy helps lymphoma patients build stronger immunity. About 26 adults with certain types of B-cell lymphoma will receive the vaccine around their CAR T treatment. The goal is to see if t…

This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, adolescents, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers. Researchers are first finding the best dose of vor…

This early-stage trial tests a new lab-made antibody called BYON4228, alone or with the cancer drug rituximab, in 17 people with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal is to check safety and find the right dose. It's the first time this drug is being tested …

This early-phase trial tests whether giving simvastatin (a cholesterol drug) and dexamethasone (a steroid) can safely prevent nerve-related side effects from axicabtagene ciloleucel (Axi-Cel) CAR-T therapy in adults with certain types of lymphoma. The study includes 37 participan…

This early-phase trial tests a combination of two drugs—copanlisib and nivolumab—in people with Richter's transformation or certain non-Hodgkin lymphomas that have become aggressive. The study aims to find the best dose and check for side effects. A total of 27 participants will …

This Phase 3 trial tests whether adding tafasitamab to lenalidomide and rituximab helps people with relapsed follicular or marginal zone lymphoma live longer without their cancer worsening. About 654 participants receive either the three-drug combo or lenalidomide plus rituximab …

This study tests a combination of two drugs, mosunetuzumab and polatuzumab vedotin, in people with untreated follicular lymphoma. The drugs work together to help the immune system find and kill cancer cells. The goal is to see how many patients achieve a complete response, meanin…

This study tests a two-step treatment for people with relapsed or refractory B-cell Non-Hodgkin lymphoma. First, patients receive a bispecific antibody therapy (Obinutuzumab and Glofitamab) to help the immune system attack cancer cells. Then, they get an infusion of CD19-CAR T ce…

This early-phase trial tests a new antibody drug called IMT-009, given alone or with the cancer pill fruquintinib, in about 67 people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand si…

This early-phase trial is testing whether giving low-dose radiation before CAR T-cell therapy is feasible and safe for people with B-cell lymphoma that has come back or not responded to treatment. About 33 participants will receive two small doses of radiation, then standard CAR …

This early-stage trial tests a personalized therapy where a patient's own immune cells are genetically modified to recognize and attack cancer cells that carry a protein called CD19. It includes adults with certain types of leukemia, lymphoma, or chronic lymphocytic leukemia that…

This early-phase trial is testing a new type of immunotherapy called tri-specific CAR T-cells that target three proteins (CD19, CD20, CD22) on cancer cells. It is for adults with B-cell lymphomas that have come back or not responded to standard treatments. The study will enroll 1…

This study tracks 56 follicular lymphoma patients to see how long their COVID-19 and other vaccine immunity lasts while they receive chemotherapy and maintenance therapy. Researchers will collect blood samples at several time points to measure immune responses. The goal is to und…

This study is looking at whether a blood test that measures cell-free DNA (cfDNA) can help doctors know how well first-line treatment is working in people with follicular lymphoma. Researchers will collect blood samples before, during, and after standard treatment, and compare cf…

This study aims to create a more accurate tool to predict whether follicular lymphoma patients will remain free of disease progression two years after their first treatment. Researchers will combine clinical information with molecular data from 370 patients to build and test this…